MX2015017539A - Composiciones nanoparticuladas y formulaciones de compuestos de piperazina. - Google Patents

Composiciones nanoparticuladas y formulaciones de compuestos de piperazina.

Info

Publication number
MX2015017539A
MX2015017539A MX2015017539A MX2015017539A MX2015017539A MX 2015017539 A MX2015017539 A MX 2015017539A MX 2015017539 A MX2015017539 A MX 2015017539A MX 2015017539 A MX2015017539 A MX 2015017539A MX 2015017539 A MX2015017539 A MX 2015017539A
Authority
MX
Mexico
Prior art keywords
nanoparticulate compositions
formulations
piperazine compounds
compositions
nanoparticulate
Prior art date
Application number
MX2015017539A
Other languages
English (en)
Other versions
MX363378B (es
Inventor
Young Bok Lee
Deog Joong Kim
Chang-Ho Ahn
Original Assignee
Rexahn Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rexahn Pharmaceuticals Inc filed Critical Rexahn Pharmaceuticals Inc
Publication of MX2015017539A publication Critical patent/MX2015017539A/es
Publication of MX363378B publication Critical patent/MX363378B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dispersion Chemistry (AREA)

Abstract

La presente invención se refiere a una composición nanoparticulada estable durante el almacenamiento de compuestos de piperazina. Asimismo, se describen las composiciones farmacéuticas que comprenden las composiciones nanoparticuladas que son útiles para el tratamiento y la prevención de enfermedades proliferativas que incluyen cáncer.
MX2015017539A 2013-06-28 2014-06-27 Composiciones nanoparticuladas y formulaciones de compuestos de piperazina. MX363378B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361840800P 2013-06-28 2013-06-28
PCT/US2014/044714 WO2014210543A1 (en) 2013-06-28 2014-06-27 Nanoparticulate compositions and formulations of piperazine compounds

Publications (2)

Publication Number Publication Date
MX2015017539A true MX2015017539A (es) 2016-04-26
MX363378B MX363378B (es) 2019-03-21

Family

ID=52115818

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015017539A MX363378B (es) 2013-06-28 2014-06-27 Composiciones nanoparticuladas y formulaciones de compuestos de piperazina.

Country Status (10)

Country Link
US (2) US9744167B2 (es)
EP (1) EP3013321B1 (es)
JP (1) JP6063090B2 (es)
KR (1) KR101741344B1 (es)
CN (1) CN105530919A (es)
AU (1) AU2014302085B2 (es)
BR (1) BR112015032262A2 (es)
CA (1) CA2913611C (es)
MX (1) MX363378B (es)
WO (1) WO2014210543A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016209480A1 (en) * 2015-06-24 2016-12-29 Intel Corporation Combined rear cover and enhanced diffused reflector for display stack
JP2018526392A (ja) 2015-09-04 2018-09-13 レクサン ファーマシューティカルズ インコーポレイテッド キノキサリニル−ピペラジンアミドの使用方法
CN110996965A (zh) 2017-05-30 2020-04-10 罗山制药股份有限公司 稳定、无菌和结晶的邻乙酰水杨酸(阿司匹林)的小瓶内沉积物
EP3928772B1 (en) 2020-06-26 2024-06-19 Algiax Pharmaceuticals GmbH Nanoparticulate composition

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU660852B2 (en) 1992-11-25 1995-07-06 Elan Pharma International Limited Method of grinding pharmaceutical substances
TW384224B (en) 1994-05-25 2000-03-11 Nano Sys Llc Method of preparing submicron particles of a therapeutic or diagnostic agent
US5718388A (en) 1994-05-25 1998-02-17 Eastman Kodak Continuous method of grinding pharmaceutical substances
US5510118A (en) 1995-02-14 1996-04-23 Nanosystems Llc Process for preparing therapeutic compositions containing nanoparticles
KR100396738B1 (ko) * 1999-03-03 2003-09-03 삼진제약주식회사 피페라진 유도체 및 그 제조방법
JP6097946B2 (ja) 2004-11-17 2017-03-22 レクサン ファーマシューティカルズ インコーポレイテッド １−［（６，７−置換−アルコキシキノキサリニル）アミノカルボニル］−４−（ヘテロ）アリールピペラジン誘導体
UA89513C2 (uk) * 2004-12-03 2010-02-10 Элан Фарма Интернешнл Лтд. Стабільна композиція з наночастинок ралоксифену гідрохлориду
CN101829061A (zh) * 2010-05-14 2010-09-15 无锡纳生生物科技有限公司 一种紫杉醇纳米颗粒组合物及其制备方法
US9012511B2 (en) * 2010-05-19 2015-04-21 Alkermes Pharma Ireland Limited Nanoparticulate cinacalcet compositions
CN103044437B (zh) * 2012-12-21 2015-08-26 上海交通大学 用于治疗肿瘤的两亲性缀合物纳米颗粒及制备方法、应用

Also Published As

Publication number Publication date
AU2014302085B2 (en) 2019-04-11
MX363378B (es) 2019-03-21
KR101741344B1 (ko) 2017-05-29
US10052321B2 (en) 2018-08-21
US20180008601A1 (en) 2018-01-11
JP6063090B2 (ja) 2017-01-18
CA2913611C (en) 2019-12-24
BR112015032262A2 (pt) 2017-07-25
US9744167B2 (en) 2017-08-29
EP3013321A1 (en) 2016-05-04
KR20150123218A (ko) 2015-11-03
JP2016515588A (ja) 2016-05-30
EP3013321B1 (en) 2020-12-09
WO2014210543A1 (en) 2014-12-31
CN105530919A (zh) 2016-04-27
EP3013321A4 (en) 2017-01-11
US20150004234A1 (en) 2015-01-01
CA2913611A1 (en) 2014-12-31
AU2014302085A1 (en) 2015-12-17

Similar Documents

Publication Publication Date Title
PH12019500176A1 (en) Heterocyclic compounds and ther uses
PH12016501790B1 (en) Pharmaceutical compositions of therapeutically active compounds
PH12016501898B1 (en) Quinoxaline derivatives useful as fgfr kinase modulators
PH12016501578A1 (en) Pharmaceutical compounds
PH12016501788B1 (en) Pharmaceutical compositions of therapeutically active compounds
IN2014MN02069A (es)
MX371108B (es) Pirimidopirimidinonas utiles como iniciadores de wee-1 cinasa.
MX2015011984A (es) Inhibidores de bromodominio de dihidro-pirrolopiridinona.
PH12015502161A1 (en) Therapeutic compounds and compositions
MX2015012005A (es) Inhibidores de bromodominio.
IN2014MN02049A (es)
PH12014502032A1 (en) Treatment of brain cancer
MX2016004114A (es) Derivados de 1,4-dihidrodioxina fusionada como inhibidores del factor de trascripcion de choque termico 1.
MX2015012416A (es) Compuestos heterociclicos y sus usos.
SG11201605868XA (en) Pharmaceutical composition for cancer treatment and pharmaceutical preparation for cancer treatment containing same composition as active ingredient
IN2013MU03641A (es)
MY180844A (en) Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions
MX363378B (es) Composiciones nanoparticuladas y formulaciones de compuestos de piperazina.
MX2016004094A (es) Composicion farmaceutica que comprende capecitabina y ciclofosfamida.